





Fact Sheet

2008 Q4 UPDATE



Corporate Profile:

Since its founding in 2000, ev3 has been dedicated to developing innovative, breakthrough and clinically proven technologies and solutions for the treatment of peripheral vascular and neurovascular diseases. ev3's products are used by endovascular specialists to treat a wide range of peripheral vascular and neurovascular diseases and disorders. The company offers a comprehensive portfolio of treatment options, including the primary interventional technologies used today – peripheral angioplasty balloons, stents, plaque excision systems, embolic protection devices, liquid embolics, embolization coils, thrombectomy catheters and occlusion balloons. More information about the company and its products can be found at www.ev3.net.



*Excluding research collaboration revenue

Analyst Coverage[†]:

Exchange: NASDAQ
Ticker: EVV

CHARLEY JONES
Barrington Research
cjones@brai.com

JASON MILLS
Canaccord Adams
jason.mills@canaccordadams.com

CHRISTOPHER WARREN
Caris & Company
cwarren@cariscompany.com

PETER BYE
Jefferies & Company, Inc.
pbye@jefferies.com

MICHAEL WEINSTEIN
JPMorgan
mike.weinstein@jpmorgan.com

DAVID LEWIS
Morgan Stanley
david.r.lewis@morganstanley.com

JOSHUA ZABLE
Natixis Bleichroeder, Inc.
joshua.zable@blr.natixis.com

THOMAS GUNDERSON
Piper Jaffray
thomas.j.gunderson@pjc.com

TOM KOUCHOUKOS
Stifel Nicolaus & Company
kouchoukost@stifel.com

RAJ DENHOY
Thomas Weisel Partners
rdenhoy@tweisel.com

BETH SENKO
Williams Capital Group
senko@willcap.com

Investor Contact:

JULIE TRACY
Sr. Vice President
Chief Communications Officer
OFFICE 949-680-1375
MOBILE 209-613-6945
jtracy@ev3.net

ev3 Inc.
Corporate World Headquarters
9600 54th Avenue North
Plymouth, MN 55442-2111

[†] ev3 is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding ev3's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of ev3 or its management. ev3 does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Recent Developments:

February 24, 2009

ev3 Inc. reported its 2008 fourth quarter and full-year financial results and its 2009 financial guidance.

Fourth Quarter Financial Results

ev3's net sales in the fourth quarter of 2008 increased 15% to \$106.1 million versus net sales of \$92.2 million in the comparable quarter of 2007. Fourth quarter 2008 revenues included approximately \$105.6 million in net product sales and approximately \$469,000 in research collaboration revenues. ev3's net loss for the fourth quarter of 2008 increased to a loss of (\$291.1) million, or (\$2.78) per common share, reflecting non-cash asset impairment charges of \$288.8 million related to our goodwill and other intangible assets. ev3's non-GAAP adjusted net income was \$7.9 million, or \$0.08 per diluted share, in the fourth quarter 2008 compared to a net loss of (\$25.0) million, or (\$0.25) per diluted share, in the fourth quarter 2007. Total weighted average diluted shares outstanding used in the per share calculations were 104.7 million and 101.9 million for the fourth quarter of 2008 and 2007, respectively.

Full-Year Financial Results

ev3's net sales for the year ended December 31, 2008 increased 49% to \$422.1 million versus \$284.2 million for the year ended December 31, 2007. For the fiscal year ended December 31, 2008, ev3's non-GAAP adjusted net income was \$9.9 million, or \$0.09 per diluted share compared to a net loss of (\$63.6) million, or (\$0.91) per diluted share for the year ended December 31, 2007. Total weighted average diluted shares outstanding used in the per share calculations were 104.7 million and 69.9 million for the years ended December 31, 2008 and 2007, respectively.

Outlook

ev3 expects fiscal year 2009 net sales to be in the range of \$415 to \$430 million. ev3 expects non-GAAP adjusted earnings per share to be in the range of \$0.38 to \$0.44 per diluted share based on approximately 105.5 million of outstanding shares. ev3's adjusted net earnings per share guidance excludes estimated amortization expense of approximately \$21.8 million and non-cash stock-based compensation of approximately \$13.4 million.

The company expects first quarter 2009 net sales to be in the range of \$95 to \$99 million and non-GAAP adjusted net earnings per share to be in the range of \$(0.03) to \$0.00 per diluted share based on approximately 105.2 million of outstanding shares. ev3's non-GAAP adjusted net earnings per share excludes estimated amortization expense of approximately \$5.9 million and non-cash stock-based compensation of approximately \$3.3 million.

To access the archived webcast and reconciliations of the non-GAAP financial measures used above to the most comparable U.S. GAAP measures, go to <http://ir.ev3.net>.

January 9, 2009

ev3 announced that Shawn McCormick was appointed Sr. Vice President and Chief Financial Officer.

January 5, 2009

ev3 presented at the 27th Annual J.P. Morgan Healthcare Conference on January 12, 2009. To access the archived webcast, go to <http://ir.ev3.net>.

December 9, 2008

ev3 announced 510(k) clearance from the U.S. Food & Drug Administration (FDA) to market its EverCross 0.035" and NanoCross 0.014" peripheral angioplasty balloon catheters. ev3 began full commercialization of the EverCross and NanoCross peripheral balloon catheters globally in January 2009.

The EverCross and NanoCross peripheral balloon catheters are designed to offer improved overall performance in peripheral angioplasty procedures. Among several new features, both catheters offer innovative beveled tip profiles for best-in-class lesion entry and a broad range of sizes, including the only 200 mm length .035" balloon available worldwide. The EverCross balloons also offer Rated Burst Pressures that compete in the high pressure balloon market without compromising ease of use.

December 3, 2008

ev3 appointed John L. Miclot to Board of Directors. Mr. Miclot is the President and Chief Executive Officer of CCS Medical, a privately held nationwide provider of various home care products for chronic diseases such as diabetes, wound care, urology and respiratory disorders.

For more information, please visit our Website at www.ev3.net



ev3 Corporate World Headquarters
Peripheral Vascular
9600 54th Avenue North
Plymouth, MN 55442-2111
USA
PH+1 763 398 7000
FX+1 763 398 7001
Tollfree +800 716 6700
www.ev3.net

ev3 Europe Headquarters
106-108 rue La Boétie
75008 Paris
France
PH+33 156 88 59 10
FX+33 156 88 59 11

ev3 Neurovascular
9775 Toledo Way
Irvine, CA 92618
USA
PH+1 949 837 3700
FX+1 949 837 2044